FI78074C - Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer. - Google Patents

Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer. Download PDF

Info

Publication number
FI78074C
FI78074C FI823246A FI823246A FI78074C FI 78074 C FI78074 C FI 78074C FI 823246 A FI823246 A FI 823246A FI 823246 A FI823246 A FI 823246A FI 78074 C FI78074 C FI 78074C
Authority
FI
Finland
Prior art keywords
methyl
pyridyloxy
hydrogen
phenyl
thioethylamines
Prior art date
Application number
FI823246A
Other languages
English (en)
Swedish (sv)
Other versions
FI78074B (fi
FI823246L (fi
FI823246A0 (fi
Inventor
Claus Schneider
Gerhard Walther
Karl-Heinz Weber
Wolf Dietrich Bechtel
Karin Boeke-Kuhn
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of FI823246A0 publication Critical patent/FI823246A0/fi
Publication of FI823246L publication Critical patent/FI823246L/fi
Application granted granted Critical
Publication of FI78074B publication Critical patent/FI78074B/fi
Publication of FI78074C publication Critical patent/FI78074C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

λ 78074
Menetelmä valmistaa farmakologisesti arvokkaita substituoituja 2-fenyyli-2-pyridyylioksi- ja -tio-etyyliamiineja. -Förfarande för framställning av farmakologiskt värdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer.
Keksinnön kohteena on menetelmä valmistaa farmakologisesti arvokkaita substituoituja 2-fenyyli-2-pyridyylioksi- ja -tio-etyyliamiine ja, joiden kaava I on / *3 0 N, X ^/«4
„ CH - CHo - N
R1 —f- I 1 x
Rs jossa
Rl ja R2/ jotka voivat olla samanlaisia tai erilaisia, ovat vety, halogeeniatomi, metyyli, metoksi, amino tai nitro, R3 on vety, halogeeni tai metyyli ja R4 ja R5, jotka voivat olla samanlaisia tai erilaisia ovat vety tai 1-2 hiiliatominen alkyyliryhmä tai ne muodostavat yhdessä typpiatomin kanssa pyrrolidino- tai morfolinorenkaan ja X on O tai S, ja niiden fysiologisesti sopivia happoadditio-suoloja.
Keksinnön mukaan uudet kaavan I mukaiset yhdisteet voidaan valmistaa saattamalla yleiskaavan II mukainen fenyylietyyli-amiini >V «-». v " '“CJr 2 78074 jossa Ri, R2, R4 ja R5 tarkoittavat samaa kuin edellä ja Y on halogeniatomi tai hydroksiryhmä, tai tämän yhdisteen happoaddi-tiosuola reagoimaan yleiskaavan III mukaisen pyridiinijohdoksen kanssa /-vz <' N (III)
R3^W
jossa R3 tarkoittaa samaa kuin edellä ja Z on hydroksi- tai merkapto-ryhmä.
Yleiskaavan II mukaisilla lähtöaineilla, joissa Y on hydroksi-ryhmä, tapahtuu kondensaatio yleiskaavan III mukaisen yhdisteen kanssa happamessa väliaineessa korotetuissa lämpötiloissa. Tässä reaktiossa tulevat kysymykseen vahvat epäorgaaniset tai orgaaniset hapot, esim. väkevät mineraalihapot kuten kloori-vetyhappo, bromivetyhappo, rikkihappo, polyfosforihappo, edelleen etikkahappoanhydridi, forforipentoksidi tai trifluori-etikkahappo.
Yleiskaavan II mukaiset fenyylietyyliamiinit, joissa Y on halo-geeniatomi, saatetaan reagoimaan yleiskaavan III mukaisen pyridiinijohdoksen kanssa parhaiten käyttämällä emäksistä ainetta ja parhaiten faasinsiirto-olosuhteissa (so. lisäämällä yhtä tai useampaa pitkäketjuista tertiääristä amiinia, kuten bentsyyli- tributyyli-ammonium-halogenidia tai tetrabutyyli-ammonium-halogenidia tai lisäämällä bentsyyli-trifenyyli-fosfoniumkloridia).
Emäksisinä aineina tulevat kysymykseen epäorgaaniset emäkset kuten alkali- tai maa-alkalihydroksidit tai -karbonaatit, orgaaniset emäkset kuten pyridiini, piperidiini, tertiääriset amiinit tai myös alkalalkoholaatit.
3 78074
Yleiskaavan I mukaiset yhdisteet, joissa R4 ja/tai R5 on vety, voidaan sinänsä tunnetulla tavalla alkyloida, esim. saattamalla reagoimaan dialkyylisulfaatin tai alkyylihalogenidin kanssa.
Lähtöaineet ovat yleisiä kemikaaleja, joita voidaan hankkia kaupasta tai jotka voidaan valmistaa yleisesti tunnetuilla menetelmillä.
Yleiskaavan I mukaiset lopputuotteet voidaan haluttaessa muuttaa tavanomaisilla menetelmillä fysiologisesti vaarattomiksi happo-additiosuoloikseen. Tähän tarkoitukseen sopivat hapoiksi sekä epäorgaaniset hapot kuten halogeenivetyhapot, rikkihappo, fos-forihappo ja aminosulfonihappo, että myös orgaaniset hapot kuten muurahaishappo, etikkahappo, propionihappo, maitohappo, glukoo-lihappo, glukoonihappo, maleiinihappo, meripihkahappo, viini-happo, bentsyylihappo, salisyylihappo, sitruunahappo, askorbii-nihappo, p-tolueenisulfonihappo tai oksietaanisulfonihappo.
Japanilaisesta julkaisusta 53 141 271 tunnetaan yhdiste, jonka kaava on
Het-Ri-Z-R2-NH-Y
jossa Y on happoryhmä. Tunnetussa yhdisteessä on ryhmät Het (esim. pyridyyli) suoraan sidottu hiiliatomiin, ei siis O tai S-atomin kautta, kuten kaavan I mukaisssa yhdisteissä. Tunnetut yhdisteet eroavat kaavan I mukaisista uusista yhdisteistä N-asyyliryhmän suhteen. Lisäksi näitä tunnettuja yhdisteitä kuvataan mahanesteen eritystä hidastavina yhdisteinä, kun taas kaavan I mukaiset yhdisteet ovat osoittautuneet käyttökelpoisiksi antidepressiivisinä yhdisteinä.
Yleiskaavan I mukaiset uudet yhdisteet ja niiden happoadditiosuo-lat ovat arvokkaita farmaseuttisia aineita; ne tehoavat hyvin 4 78074 antidepressiiveille spesifisissä biokemiallisissa ja farmakologisissa koejärjestelyissä. Siten niillä on kyky estää hiirillä tertabentsaiinilla indusoitua ptoosistaj EDsg-arvo on suuruusluokkaa 1 mg/kg. Tätä testiä käytetään antidepressiivisten ominaisuuksien standarditestinä (International Journal of Neuropharmacology 8, 73 (1969)).
Keksinnön mukaisilla yhdisteillä on osoittautunut olevan erittäin suotuisa vaikutus myös testissä, jossa tutkitaan reserpiini antagonismia, so. reserpiinillä aiheutetun hypotermiavaikutuksen kumoamista antidepressiivisesti tehokkailla aineilla. Lisäksi on todettu, että ne estävät serotoniinin ja adrenaliinin palautumista neuroneihin.
Uudet yhdisteet ovat erityisen arvokkaita johtuen rakenteesta, joka poikkeaa tähän mennessä tunnetuista antidepressiiveistä; niiden vaikutus on yhtä hyvä tai parempi kuin tunnettujen kaupallisten tuotteiden ja samalla niillä on alhaisempi toksisuus.
Erityisesti maininnan arvoisia ovat sellaiset yleiskaavan I mukaiset yhdisteet, joissa on bromiatomi p-asemassa, X on happiatomi, R2 on vety, R3 ja R4 tarkoittavat metyyliryhmiä. Erityisen huomattavia ovat seuraavat yhdisteet: 2-(p-bromifenyyli)-2-(pyridyyli)-(3)-oksi)-N,N-dimetyyli-etyyli-amiini.
Farmakologiset kokeet
On tunnettua, että erilaiset depressiomuodot aiheuttavat bio-geenisten amiinien, erityisesti noradrenaliinin ja serotoniinin, vähenemisen tietyillä alueilla aivoissa. Biogeenisia amiineja voidaan näin ollen lisätä estämällä imeytymisen neurooneihin.
Farmakologinen koe on suoritettu homogenisoiduilla eristetyillä rotan aivoilla. Näin saatu synoptosoni-suspensio inkuboitiin 5 78074 deutterisoidulla noradrenaliinilla tai serotonilla ja erilaisilla koeliuoksen pitoisuuksilla vedessä 10 minuuttia lämpötilassa 37°C. Inkuboinnin päätyttyä väliaine erotettiin suodattamalla ja synaptosoni-suspension radioaktiviteetti mitattiin.
Lisäksi suoritettiin kontrollikoe ilman koeyhdisteitä radioaktiivisen amiinin adsorptiomäärän määrittämiseksi. Arvolla IC50 tarkoitetaan sitä koeyhdisteen määrää mooleissa, joka on riittävä 50 %:n adsorptio (Uptake) estämiseksi. Keksinnön mukaan valmistetuilla uusilla yhdisteillä arvot ovat suuruusluokkaa 10~6 _ io~7 moolia. Koetulokset on esitetty seuraavassa taulukossa.
Seroto- Noradre-
Tetra- niini naliini- benatsiini esto esto
Yhdiste hiiri, ED50 IC50 (mol) IC50 (mol) 2-(3,4-dikloorifenyyli)- 2-(3-pyridyylioksi)-N,N- dimetyylietyyliamiini 1,76 0,345*10-6 0,086*10“^ 2-(p-bromifenyyli)-2-(4-pyridyylioksi)-N,N- dimetyylietyyliamiini 2,0 0,42 ·10“6 0,75 ·10-6 2-(p-bromifenyyli)-2-(3-pyridyylioksi)-N,N- dimetyylietyyliamiini 1,1 0,4 ·10“6 0,54 ·10“6 2-(2-kloori-4-bromife-nyyli)-2-(3-pyridyyli-oksi)-N,N-dimetyyli-etyylamiini 3,6 6 78074 (ed. sivulta jatkoa)
Seroto- Noradre-
Tetra- niini naliini- benatsiini esto esto
Yhdiste hiiri, ED50 IC50 (®ol) IC50 (mol) 2-fenyyli-2-(3-pyridyy-lioksi)-N,N-dimetyyli- etyyliamiini 4,7 2,7 ·10“® 4,3 ·10"6 2-fenyyli-2-(2-pyridyy-lioksi)-N,N-dimetyyli- etyyliamiini 1,6 7,8 »10-^ 1,2 *10”® 2-(4-bromi-6-kloorife-nyyli)-2-(2-pyridyyli-oksi)-N,N-dimetyyli- etyyliamiini 8,4 - 0,26 ·10-® [2-(4-bromifenyyli)-2-(pyridyyli-(2)-tio)-N,N-dimetyyli etyyli- amiini ]____________________2X9_________-_________
Seuraavat esimerkit selventävät keksintöä lähemmin:
Esimerkki 1 2-p-bromifenyyli-2-(3-pyridyylioksi)-N,N-dimetyyli-etyyliamiini- dihydrokloridi 29,9 g 2-kloori-2-p-bromifenyyli-N,N-dimetyyli-etyyliamiini-hydrokloridia (0,1 moolia) ja 14,3 g 3-hydroksipyridiiniä (0,15 moolia) kuumennetaan 16 tuntia refluksoiden seoksessa, joka sisältää 150 ml 25 %:sta natriumhydroksidia ja 150 ml tolu- 7 78074 eenia sekä 0,5 g bentsyylitrifenyylifosfoniumkloridia. Liuotin tislataan pois orgaanisesta faasista, jolloin jäljelle jää jäännös, joka liuotetaan alkoholiin. Otsikkoyhdisteen dihydrokloridi saadaan suolahapolla. Puhdistamista varten otsikkoyhdiste käsitellään sykloheksaanissa aktiivihiilellä ja piimaalla. Dihydro-kloridin saanto on 20 g (44 % teoreettisesta). Sulamispiste 128 - 129°C (etanoli).
Edellä kuvatulla menetelmällä saatiin seuraavat yleiskaavan I mukaiset yhdisteet:
Pyridyy-
Esim. R2 R3 R4 R5 X iin Sp.°C
no.___________________________________________liitos_______ 2 H H H CH3 CH3 O 2 162 - 162 3 H H H CH3 CH3 O 3 151 - 152 4 4-Br H 2-C1 CH3 CH3 O 3 135 - 136 5 4-Br H 5-C1 CH3 CH3 O 2 234 - 235 6 4-Br H 6-C1 CH3 CH3 O 2 193 - 194 7 4-Br H H CH3 CH3 O 2 162 - 163 8 4-Br H H CH3 CH3 S 2 190 - 191 9 4-Br H H Morfoliini O 3 95-97 10 4-Br H H Pyrrolidiini 0 3 152 - 153 11 4-Br H H CH3 CH3 O 4 112 (haj) 12 4-C1 H H CH3 CH3 O 3 126 (haj) 13 3-C1 4-C1 H CH3 CH3 O 3 175 - 176 14 4-OCH3 H H CH3 CH3 O 3 103 - 105 15 3-OCH3 H H H H O 2 222 - 223 16 4-CH3 H H CH3 CH3 O 3 180 - 181

Claims (2)

  1. 8 78074 Patenttivaatimus Menetelmä valmistaa farmakologisesti arvokkaita substituoituja 2-fenyyli-2-pyridyylioksi- ja -tio-etyyliamiineja, joiden kaava I on /3 0 ... R2 X ^ R4 — CH - CH2 - N ">-ζχ jossa Rl ja R21 jotka voivat olla samanlaisia tai erilaisia, ovat vety, halogeeniatomi, metyyli, metoksi, amino tai nitro, R3 on vety, halogeeni tai metyyli ja R4 ja R5, jotka voivat olla samanlaisia tai erilaisia ovat vety tai 1-2 hiiliatominen alkyyliryhmä tai ne muodostavat yhdessä typpiatomin kanssa pyrrolidino- tai morfolinorenkaan ja X on O tai S, ja niiden fysiologisesti sopivia happoadditio-suoloja, tunnettu siitä, että yleiskaavan II mukainen fenyylietyyliamiini RaW T R f* >1- CH - CH2 - N (II) l—h \n r5 jossa Rl, R2, R4 ja R5 tarkoittavat samaa kuin edellä ja Y on halogeeniatomi tai hydroksiryhmä, tai tämän yhdisteen happo-additiosuola saatetaan reagoimaan yleiskaavan III mukaisen pyridiinijohdoksen kanssa 9 78074 β 'βι dii) R3 jossa R3 on vety, halogeeniatomi tai metyyliryhmä ja Z on hydroksi- tai merkaptoryhmä, ja näin saatu lopputuote mahdollisesti muunnetaan fysiologisesti sopivaksi happoadditio-suolaksi. Förfarande för framställning av farmakologiskt värdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer med formeln I /3 0
  2. 2 Xv-v. X ^ r4 "‘-O- H"CH2 ’ "xr5 där Rl och R2* vilka kan vara likadana eller oiikä, är väte, en halogenatom, metyl, metoxi, amino eller nitro, R3 Mr väte, halogen eller metyl och R4 och R5, vilka kan vara likadana eller olika, är väte eller en alkylgrupp med 1-2 kolatomer eller de bildar tillsammans med kväveatomen en pyrrolidino- eller morfolinoring och X är 0 eller S, och deras fysiologiskt lämpliga syraadditions-salter, kännetecknat därav, att en fenyletylamin med den allmänna formeln II
FI823246A 1981-09-28 1982-09-22 Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer. FI78074C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19813138550 DE3138550A1 (de) 1981-09-28 1981-09-28 Substituierte 2-phenyl-2-(pyridyloxy)-ethylamine und isostere verbindungen, verfahren zu ihrer herstellung und verwendung
DE3138550 1981-09-28

Publications (4)

Publication Number Publication Date
FI823246A0 FI823246A0 (fi) 1982-09-22
FI823246L FI823246L (fi) 1983-03-29
FI78074B FI78074B (fi) 1989-02-28
FI78074C true FI78074C (fi) 1989-06-12

Family

ID=6142812

Family Applications (1)

Application Number Title Priority Date Filing Date
FI823246A FI78074C (fi) 1981-09-28 1982-09-22 Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer.

Country Status (21)

Country Link
US (1) US4666910A (fi)
EP (1) EP0075752B1 (fi)
JP (1) JPS5869865A (fi)
KR (1) KR880002705B1 (fi)
AR (1) AR231534A1 (fi)
AT (1) ATE18551T1 (fi)
AU (1) AU550614B2 (fi)
CA (1) CA1171086A (fi)
DE (2) DE3138550A1 (fi)
DK (1) DK156718C (fi)
ES (1) ES8308543A1 (fi)
FI (1) FI78074C (fi)
GB (1) GB2106902B (fi)
GR (1) GR77657B (fi)
IE (1) IE53959B1 (fi)
IL (1) IL66870A (fi)
NO (1) NO159999C (fi)
NZ (1) NZ202015A (fi)
PH (1) PH23219A (fi)
PT (1) PT75611B (fi)
ZA (1) ZA827055B (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8320699D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Ethylenediamines
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102639D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US6800652B2 (en) 2002-08-16 2004-10-05 Pfizer Inc. Diaryl compounds
GB0219154D0 (en) * 2002-08-16 2002-09-25 Pfizer Ltd Diaryl compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
CN1886398A (zh) * 2003-10-09 2006-12-27 米伦纽姆医药公司 作为Xa因子抑制剂的经硫醚取代的苯甲酰胺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734845A (en) * 1956-02-14 Aqueous suspension of procaine penicil-
US2734846A (en) * 1956-02-14 Aqueous suspension of procaine penicil-
FR1511398A (fr) * 1966-02-16 1968-01-26 Takeda Chemical Industries Ltd Procédé de préparation de nouveaux dérivés de picoline
BE790592A (fi) * 1971-10-28 1973-04-26 Oreal
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents

Also Published As

Publication number Publication date
DE3138550A1 (de) 1983-04-07
GR77657B (fi) 1984-09-25
IL66870A0 (en) 1982-12-31
DK156718C (da) 1990-03-05
ES515972A0 (es) 1983-09-16
CA1171086A (en) 1984-07-17
NZ202015A (en) 1985-11-08
FI78074B (fi) 1989-02-28
AU8873882A (en) 1983-04-14
AR231534A1 (es) 1984-12-28
DE3269839D1 (en) 1986-04-17
EP0075752A2 (de) 1983-04-06
PT75611B (de) 1985-12-09
EP0075752A3 (en) 1984-03-21
ES8308543A1 (es) 1983-09-16
AU550614B2 (en) 1986-03-27
NO159999B (no) 1988-11-21
GB2106902B (en) 1985-08-07
US4666910A (en) 1987-05-19
ZA827055B (en) 1984-05-30
IE822330L (en) 1983-03-28
NO823253L (no) 1983-03-29
JPS5869865A (ja) 1983-04-26
DK156718B (da) 1989-09-25
FI823246L (fi) 1983-03-29
KR840001555A (ko) 1984-05-07
FI823246A0 (fi) 1982-09-22
NO159999C (no) 1989-03-01
PT75611A (de) 1982-10-01
DK428582A (da) 1983-03-29
KR880002705B1 (ko) 1988-12-26
EP0075752B1 (de) 1986-03-12
IE53959B1 (en) 1989-04-26
PH23219A (en) 1989-06-06
GB2106902A (en) 1983-04-20
IL66870A (en) 1986-02-28
ATE18551T1 (de) 1986-03-15
JPH0316952B2 (fi) 1991-03-06

Similar Documents

Publication Publication Date Title
FI78074C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerade 2-fenyl-2-pyridyloxi- och -tio-etylaminer.
SU1597096A3 (ru) Способ получени производных дифенилпропиламина или их фармакологически приемлемых солей
NO813850L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser
HU198033B (en) Process for production of n-benzhydril-diaz-cycloalkilalcane-anilides and medical preparatives containing these compounds as active substance
NZ203724A (en) Polymethylene imine substituted pyrimidine and triazine derivatives and pharmaceutical compositions
DE1795587A1 (de) Neue Nitrosoverbindungen und Verfahren zu ihrer Herstellung
US5244894A (en) 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics
FI66374B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 3-fluor-10-piperazino-8-substituerade 10,11-dihydrodibenso(b,f)tiepiner
FI78909B (fi) Foerfarande foer framstaellning av 2-piperazinylpyrimidinderivat anvaendbara som laekemedel.
DD294023A5 (de) Therapeutische mittel
FI86545B (fi) Foerfarande foer framstaellning av terapeutiskt verkande 1-aroyl-4-aralkylpiperaziner.
DE2707268A1 (de) Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung
Manoury et al. Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl) alkyl 2-aminobenzoates and 2-aminonicotinates
US3306903A (en) 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates
US3383415A (en) 2-tertiary-aminomethyl-nu-(loweralkyl) anilines
FI63566C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter
Cowden et al. Flavins as potential antimalarials. 2. 3-Methyl-10-(substituted-phenyl) flavins
Petigara et al. Synthesis and central nervous system depressant activity of new piperazine derivatives. I
US2470109A (en) Heterocyclic amines
HU186968B (en) Process for preparing cinnamoly-anthranilic acid derivatives substituted in the nucleus
PL141540B1 (en) Process for preparing n-substituted 1-oxide of nicotinic acid amide
FI62664C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 6-piperazinyl-11-metylen-morfantridin-derivat
US3057861A (en) Basic derivatives of trifluoromethyl-
US4062891A (en) N-formyl-2,3,5,6-dibenzobicyclo[5.1.0]octan-4-methylamine
US3819707A (en) 4-(aminoalkylamino)-2-halobenzyl alcohols

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: BOEHRINGER INGELHEIM KG